Gold: Uptrend Intact Despite Coronavirus Treatment Hopes

On Monday, spot gold marked a day-high near $1,962 before ending 0.6% lower at $1,929, amid coronavirus treatment hopes...

Gold 1

On Monday, spot gold marked a day-high near $1,962 before ending 0.6% lower at $1,929. The U.S. Food and Drug Administration has given emergency authorization to use blood plasma, from people who have recovered from the coronavirus, to treat severe COVID-19 patients.

On the other hand, Financial Times reported that the U.S. government is considering a fast-track approval of COVID-19 vaccine being developed by AstraZeneca and Oxford University. However, the report was denied by the pharmaceutical giant.

From a technical point of view, spot gold's bullish channel remains intact as shown on the daily chart. In fact, a bullish shooting star candlestick may have formed yesterday, signaling a potential upturn after a recent decline. The level at $1,880 may be considered as the nearest support, with prices trending to test the 1st and 2nd resistance at $2,015 and $2,075 on the upside. Alternatively, a break below $1,880 may flag risks to the downside and the next support at $1,823 might be exposed.

Source: TradingView, Gain Capital

Build your confidence risk free

More from Gold

Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.